An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation

Trial Profile

An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Apixaban (Primary) ; Vitamin K antagonists
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms AXAFA; AXAFA-AFNET5
  • Most Recent Events

    • 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Apr 2017 Planned End Date changed from 1 Oct 2017 to 1 Sep 2017.
    • 11 Feb 2015 New source identified and integrated ISRCTN: Current Controlled Trials record (ISRCTN87711003 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top